Tag: Liminal BioSciences Inc (NASDAQ: LMNL)


Liminal BioSciences Inc (NASDAQ: LMNL) Receives FDA Approval For Its Ryplazim To Cure Patients With Type 1 Hypoplasminogenia

The US FDA approved Ryplazim of Prometic Biotherapeutics Inc, a subsidiary of Liminal BioSciences Inc (NASDAQ: LMNL), to treat patients suffering from hypoplasminogenia.  Ryplazim is the first approved drug in the market to treat this rare genetic disorder. Liminal assessed Ryplazim efficacy in adult patients and pediatric patients with hypoplasminogenia […]